The Global Tissue Engineering-based Regeneration Products market is projected to grow at a compound annual growth rate (CAGR) of 33.7% from 2022 to 2030. Integrating scaffolds, cells, and biologically active chemicals to create functioning tissues is referred to as tissue engineering. Tissue engineering emerged from the field of biomaterials development and referred to the practice. Tissue engineering aims to put together functional constructions to repair, maintain, or otherwise improve entire organs or damaged tissues. It is a large field that includes tissue engineering but also incorporates research on self-healing, when the body uses its systems, sometimes with the help of foreign biological material, to recreate cells and rebuild tissues and organs. Regenerative medicine is one of the more recent developments in the field of medicine. Many complex and more sophisticated tissue reconstructions have been successfully performed thanks to a novel technology. This indicates that more complex tissue engineering treatments may be conceivable in the near future. The market for tissue engineering will likely experience significant growth in the near future as a result of the rapid pace of innovation that is currently taking place in this sector, as well as the recent shift in consumer preference away from conventional transplant procedures and toward regeneration products that are based on tissue engineering.
Developments in stem cell technology and tissue engineering, an increase in the number of clinical studies for regenerative medicine and tissue engineering, and rising financing for tissue engineering research are all factors that are propelling the industry forward. Chronic diseases, including CVD, cancer, diabetes, ulcers, and genetic disorders like cystic fibrosis, have grown substantially in recent decades. Diabetes and obesity can increase the prevalence and complexity of wounds such as infections, ulcerations (leg or foot ulcers), and surgical wounds, requiring costly therapies, which will turn into high demand for engineered regenerative products, pushing the market upside.
While some Tissue Engineering-based Regeneration Products show promise as an alternative to organ donation, they are not yet generally used due to their prohibitively high prices and the difficulties in obtaining reimbursements and insurance coverage. An inability to educate patients is another potential growth-limiting factor in the years ahead. Scaffolds have issues that include infections, mechanical failure, and immunogenic reactions to implanted materials. The expansion of the market will be stunted as a result.
The Tissue Engineering-based Regeneration Products Market is categorized into four segments Type of Grafts, area of application, type of material scaffold and type of end-user. By type of graft, it is segmented into allografts, autografts and xenografts. Whereas area of application includes bone healing, burn Healing, Surgical Healing, Wound Healing, and Others. In the case of a type of material scaffold, the segment contains Bone Tissue, Collagen-based Tissue, Human Placental Tissue, Other Animal Based Tissue, Other Human Tissue, Stem Cells and Others Tissues. In the end, the fourth category is end-user, which consists of Ambulatory Surgical Centers, Hospitals and Specialty Clinics.
By the region, North America will lead the Tissue Engineering-based Regeneration Products Market in the forecasting period 2022-2030 as the funding and government investment are increasing continuously.
The prominent market companies are AlloSource, BioTissue, Integra Lifesciences Corporation , MiMedx, Organogenesis, Inc., Smith +Nephew, Tissue Regenix, VIVEX Biologics, Alliqua BioMedical, Inc., MISONIX, Inc., Arthrex, Inc., B. Braun Melsungen AG, BARD, A Becton, Dickinson Company, ConMed Corporation, Globus Medical, Inc., Lattice Biologics Ltd., Osiris Therapeutics, Inc., Straumann, Xtant Medical, and Zimmer Biomet Holdings, Inc.
- AlloSource
- BioTissue
- Integra Lifesciences Corporation
- MiMedx
- Organogenesis, Inc.
- Smith +Nephew
- Tissue Regenix
- VIVEX Biologics
- Alliqua BioMedical, Inc.
- MISONIX, Inc.
- Arthrex, Inc.
- Braun Melsungen AG
- BARD, A Becton, Dickinson Company
- ConMed Corporation
- Globus Medical, Inc.
- Lattice Biologics Ltd.
- Osiris Therapeutics, Inc.
- Straumann
- Xtant Medical
- Zimmer Biomet Holdings, Inc.
Global Tissue Engineering-based Regeneration Products Market, by Area of Application, 2022-2030 (Value US$ Mn)
